What is Bicara Therapeutics's pre-tax income?

Bicara Therapeutics (BCAX) reported pre-tax income of -$56.16M in Q1 2026.

How has Bicara Therapeutics's pre-tax income changed year-over-year?

Bicara Therapeutics's pre-tax income decreased by 52.7% year-over-year, from -$36.77M to -$56.16M.

What does pre-tax income mean?

Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Bicara Therapeutics (BCAX) Pre-Tax Income

Screener

Pre-Tax Income at other companies

Eli LillyLLY

$9.25B+36.4%

AmgenAMGN

$2.77B+76.5%

Arcus BiosciencesRCUS

-$91M—

Inhibrx Biosciences, Inc.INBX

-$33.44M+22.8%

Kura OncologyKURA

-$73.33M-28.2%

Aurinia PharmaceuticalsAUPH

$48.79M+120%

Segments

By segment

See full

Reportable Segment-$56.16M-52.7%

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.81B+217%

Enterprise value$1.49B+1,000%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.

Filed: May 11, 2026, 4:03 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001628280-26-033429

Line item	Three Months Ended March 31, 2026	Three Months Ended March 31, 2025
Other income
Interest income	4,083	5,014
Total other income	4,083	5,014
Net loss before income taxes	(56,159)	(36,774)
Income tax expense	(52)	(72)
Net loss	$(56,211)	$(36,846)
Net Loss per share, basic and diluted	$(0.93)	$(0.68)
Weighted-average number common shares outstanding, basic and diluted	60,717,041	54,456,515

Item 1. Financial Statements (Unaudited)

FAQ

What is Bicara Therapeutics's pre-tax income?: Bicara Therapeutics (BCAX) reported pre-tax income of -$56.16M in Q1 2026.
How has Bicara Therapeutics's pre-tax income changed year-over-year?: Bicara Therapeutics's pre-tax income decreased by 52.7% year-over-year, from -$36.77M to -$56.16M.
What does pre-tax income mean?: Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.